Close
Close
Finance News

Agios Announces Pricing of $475 Million Public Offering of Common Stock

4.0
4.0 from 2 votes
Friday, January 19, 2018

CAMBRIDGE, Mass. - Agios Pharmaceuticals, Inc. (Nasdaq:AGIO)announced that it has priced an underwritten public offering of 7,089,553 shares of common stock at a price to the public of $67.00 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $475 million. All of the shares in the offering are to be sold by Agios. Agios has also granted the underwriters a 30-day option to purchase from it up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. Closing of the offering is expected to occur on or about January 23, 2018, subject to customary closing conditions.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. RBC Capital Markets, LLC and SunTrust Robinson Humphrey, Inc. are serving as lead managers for the offering.

The shares are being offered by Agios pursuant to an automatically effective shelf registration statement that has been filed with the Securities and Exchange Commission ("SEC"). A preliminary prospectus supplement relating to, and describing the terms of, the offering has been filed with the SEC and is available on the SEC's web site at www.sec.gov.

Copies of the final prospectus supplement and the accompanying prospectus relating to this offering, when available, can be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 866-803-9204; Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 866-471-2526, facsimile: 212-902-9316, e-mail: prospectus-ny@ny.email.gs.com; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at (631) 274-2806.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Agios Pharmaceuticals, Inc.

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics.

Contacts:

Kendra Adams, Senior Director, Investor & Public Relations
Email: Kendra.Adams@agios.com
Phone: 617-844-6407

Renee Leck, Senior Manager, Investor & Public Relations
Email: Renee.Leck@agios.com
Phone: 617-649-8299

Source: Agios Pharmaceuticals
4.0
4.0 from 2 votes
Free Newsletter
Videos